Thomssen C - Search Results

1

Zurich Consensus: German Expert Opinion on the St. Gallen Votes on 15 March 2009 (11th International Conference at St. Gallen: Primary Therapy of Early Breast Cancer).

Beckmann MW, Blohmer JU, Costa SD, Diedrich K, Diel I, Eiermann W, Friese K, Gerber B, Harbeck N, Hilfrich J, Janni W, Jaenicke F, Jonat W, Kaufmann M, Kiechle M, Koehler U, Kreienberg R, von Minckwitz G, Moebus V, Nitz U, Schneeweiss A, Thomssen C, Wallwiener D. Beckmann MW, et al. Among authors: thomssen c. Breast Care (Basel). 2009;4(2):109-116. doi: 10.1159/000212164. Epub 2009 Apr 24. Breast Care (Basel). 2009. PMID: 21049070 Free PMC article.

2

Invasion marker PAI-1 remains a strong prognostic factor after long-term follow-up both for primary breast cancer and following first relapse.

Harbeck N, Thomssen C, Berger U, Ulm K, Kates RE, Höfler H, Jänicke F, Graeff H, Schmitt M. Harbeck N, et al. Among authors: thomssen c. Breast Cancer Res Treat. 1999 Mar;54(2):147-57. doi: 10.1023/a:1006118828278. Breast Cancer Res Treat. 1999. PMID: 10424405

3

Prognostic impact of proteolytic factors (urokinase-type plasminogen activator, plasminogen activator inhibitor 1, and cathepsins B, D, and L) in primary breast cancer reflects effects of adjuvant systemic therapy.

Harbeck N, Alt U, Berger U, Krüger A, Thomssen C, Jänicke F, Höfler H, Kates RE, Schmitt M. Harbeck N, et al. Among authors: thomssen c. Clin Cancer Res. 2001 Sep;7(9):2757-64. Clin Cancer Res. 2001. PMID: 11555589

4

Clinical utility of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 determination in primary breast cancer tissue for individualized therapy concepts.

Harbeck N, Schmitt M, Kates RE, Kiechle M, Zemzoum I, Jänicke F, Thomssen C. Harbeck N, et al. Among authors: thomssen c. Clin Breast Cancer. 2002 Aug;3(3):196-200. doi: 10.3816/CBC.2002.n.023. Clin Breast Cancer. 2002. PMID: 12196277 Review.

5

[u-Plasminogen activator (urinary plasminogen activator, urokinase) (uPA) and its PA-1 type 1 inhibitor are not only prognostically but also predictively significant and support clinical decisions on therapy in primary carcinoma of the breast].

Harbeck N, Thomssen C. Harbeck N, et al. Among authors: thomssen c. Zentralbl Gynakol. 2003 Sep;125(9):362-7. doi: 10.1055/s-2003-43036. Zentralbl Gynakol. 2003. PMID: 14569518 German.

6

Clinical relevance of prognostic factors in axillary node-negative breast cancer.

Thomssen C, Jänicke F, Harbeck N. Thomssen C, et al. Onkologie. 2003 Oct;26(5):438-45. doi: 10.1159/000072976. Onkologie. 2003. PMID: 14605459 Review.

7

Anthracycline and trastuzumab in breast cancer treatment.

Untch M, Himsl I, Kahlert S, Lueck HJ, Eidtmann H, Du Bois A, Meerpohl HG, Thomssen C, Harbeck N, Jackisch C, Kreienberg R, Emons G, Wallwiener D, Wiese W, Schaller G, Kuhn W, Muscholl M, Pauschinger M, Langer B. Untch M, et al. Among authors: thomssen c. Oncology (Williston Park). 2004 Dec;18(14 Suppl 14):59-64. Oncology (Williston Park). 2004. PMID: 15685838 Free article. Clinical Trial.

8

Bendamustine prolongs progression-free survival in metastatic breast cancer (MBC): a phase III prospective, randomized, multicenter trial of bendamustine hydrochloride, methotrexate and 5-fluorouracil (BMF) versus cyclophosphamide, methotrexate and 5-fluorouracil (CMF) as first-line treatment of MBC.

von Minckwitz G, Chernozemsky I, Sirakova L, Chilingirov P, Souchon R, Marschner N, Kleeberg U, Tsekov C, Fritze D, Thomssen C, Stuart N, Vermorken JB, Loibl S, Merkle Kh, Kaufmann M. von Minckwitz G, et al. Among authors: thomssen c. Anticancer Drugs. 2005 Sep;16(8):871-7. doi: 10.1097/01.cad.0000175587.31940.19. Anticancer Drugs. 2005. PMID: 16096436 Clinical Trial.

9

DNA-methylation of the homeodomain transcription factor PITX2 reliably predicts risk of distant disease recurrence in tamoxifen-treated, node-negative breast cancer patients--Technical and clinical validation in a multi-centre setting in collaboration with the European Organisation for Research and Treatment of Cancer (EORTC) PathoBiology group.

Maier S, Nimmrich I, Koenig T, Eppenberger-Castori S, Bohlmann I, Paradiso A, Spyratos F, Thomssen C, Mueller V, Nährig J, Schittulli F, Kates R, Lesche R, Schwope I, Kluth A, Marx A, Martens JW, Foekens JA, Schmitt M, Harbeck N; European Organisation for Research and Treatment of Cancer (EORTC) PathoBiology group. Maier S, et al. Among authors: thomssen c. Eur J Cancer. 2007 Jul;43(11):1679-86. doi: 10.1016/j.ejca.2007.04.025. Epub 2007 Jun 29. Eur J Cancer. 2007. PMID: 17601725

10

uPA and PAI-1 in breast cancer: review of their clinical utility and current validation in the prospective NNBC-3 trial.

Annecke K, Schmitt M, Euler U, Zerm M, Paepke D, Paepke S, von Minckwitz G, Thomssen C, Harbeck N. Annecke K, et al. Among authors: thomssen c. Adv Clin Chem. 2008;45:31-45. doi: 10.1016/s0065-2423(07)00002-9. Adv Clin Chem. 2008. PMID: 18429492 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

346 results

Search Page

Filters